Share This Page
Drug Price Trends for NDC 00019-0952
✉ Email this page to a colleague
Average Pharmacy Cost for 00019-0952
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00019-0952
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00019-0952
Introduction
The drug associated with NDC 00019-0952 is Gazyva (obinutuzumab), marketed by Genentech. Gazyva is a monoclonal antibody approved for use in certain hematologic malignancies. Understanding its market dynamics and price trajectory is essential for stakeholders, including healthcare providers, payers, and investors.
This comprehensive analysis explores current market conditions, competitive landscape, regulatory considerations, pricing strategies, and future price projections, enabling informed decision-making.
Product Overview and Indications
Gazyva (obinutuzumab) received FDA approval primarily for:
- Chronic lymphocytic leukemia (CLL) in combination with chlorambucil for treatment-naïve and relapsed or refractory patients.
- Follicular lymphoma (FL) in combination with bendamustine and rituximab, as well as for relapsed cases.
Obinutuzumab’s mechanism involves targeting CD20 on B-cells, inducing cell death. Its profile as an enhanced anti-CD20 agent was designed to improve outcomes over earlier therapies like rituximab.
Market Landscape
Epidemiology and Patient Population
- Chronic Lymphocytic Leukemia (CLL): Estimated incidence in the U.S. is approximately 20,000 new cases annually as of 2022[1].
- Follicular Lymphoma (FL): Estimated 15,000 new cases annually in the U.S.[2].
The total addressable market in the U.S. is roughly 35,000 new patients per year, with a significant proportion likely to receive biologic therapy with agents like Gazyva.
Competitive Landscape
Gazyva's primary competitors include:
- Rituximab (Rituxan): The first CD20 monoclonal antibody, with extensive use for CLL and FL.
- Obinutuzumab (Gazyva) vs. Rituximab: Clinical trials, such as CLL11 and GALLIUM, suggest improved progression-free survival (PFS) with Gazyva, leading to preferred positioning in certain indications[3].
Other competitors include newer CD20 antibodies and biosimilars anticipated to impact pricing and market share.
Market Penetration & Usage Trends
Implementation of Gazyva has seen steady growth driven by:
- Evidence from Phase III trials supporting efficacy.
- Preferential use in combination therapies.
- Adoption by large oncology centers.
However, uptake varies regionally, influenced by formulary restrictions, clinician familiarity, and treatment guidelines.
Pricing Dynamics
Current Pricing Metrics
As of early 2023, the wholesale acquisition cost (WAC) in the U.S. for Gazyva is approximately $6,650 per 100 mg vial, with a typical treatment course involving multiple vials. The overall per-treatment cost can range between $20,000 and $50,000, depending on dosing regimens.
Reimbursement and Payer Strategies
Reimbursement patterns are influenced by:
- Medicare/Medicaid: Negotiated prices and approved use.
- Commercial insurers: Formularies and preferred drug lists.
- Biosimilar competition: Biosimilars entering the market may exert price pressures, although Gazyva retains a premium position due to clinical benefits.
Price Trends and Drivers
Factors influencing price stability or decline include:
- Patent exclusivity: Market exclusivity extends into the next decade, supporting premium pricing.
- Biosimilar entry: Pending biosimilar launches could reduce prices by 20-30% or more.
- Manufacturing costs: Biologics manufacturing complexity sustains higher prices.
- Market demand: Rising incidence rates and expanded indications bolster revenue prospects.
Regulatory and Patent Status
- Patent protection:** Extends U.S. market exclusivity until approximately 2028-2030.
- Regulatory approvals: The drug’s indications continue expanding, fostering sustained demand.
- Potential biosimilar approvals: Several biosimilar candidates have received regulatory approval in other regions, with U.S. approvals anticipated within the next 2-5 years.
This landscape will influence price trajectories directly, as biosimilar competition typically triggers price reductions.
Future Price Projections
Short to Mid-Term Outlook (Next 3-5 Years)
Given current market conditions, Gazyva’s price per treatment is projected to stabilize in the short term, supported by patent protection and ongoing clinical adoption. However, biosimilar competition will likely lead to moderate price erosion, estimated at approximately 10-15% over the next 2-3 years once biosimilars gain market share.
Long-Term Projections (Next 5-10 Years)
- Patent expiration impact: Once patents expire around 2028-2030, biosimilar entry will precipitate substantial price declines—possibly 25-40% below current levels.
- Market penetration of biosimilars: If biosimilar uptake reaches 60-80%, the resultant competition could reduce Gazyva's price to approximately $4,000 - $5,000 per 100 mg vial.
- Treatment innovation: The development of next-generation biologics with improved efficacy or safety may shift demand dynamics, impacting pricing.
Pricing Scenario Summary
| Timeline | Price Trend | Expected Price Range |
|---|---|---|
| 2023-2025 | Price stability, slight decline | $20,000 - $50,000 per course |
| 2026-2028 | Biosimilar competition escalation | $15,000 - $35,000 per course |
| 2029-2032 | Patent expiry and biosimilar widespread adoption | $10,000 - $20,000 per course |
Commercial Strategies and Market Opportunities
- Value-based contracting: Engaging payers with outcome-based agreements may support premium pricing.
- Expanded indications: Clinical trials for new indications could broaden market share.
- Access optimization: Early engagement with formulary committees can cement Gazyva’s position over biosimilars.
- Cost management: Manufacturing efficiencies and potential biosimilar licensing could mitigate pricing pressures.
Key Takeaways
- Market Position: Gazyva remains a leading therapy for CLL and FL, supported by clinical superiority over some competitors.
- Pricing Outlook: The current premium pricing is expected to decline modestly in the near term due to biosimilar entry, with significant reductions post-patent expiry.
- Competitive Forces: Biosimilar proliferation will be a primary driver of future price erosion, emphasizing the need for strategic planning.
- Regulatory Factors: Patent protection and indication expansion will sustain pricing power until mid-to-late 2020s.
- Investment and Business Decisions: Stakeholders should monitor biosimilar development, clinical trial outcomes, and payer strategies to optimize positioning.
Frequently Asked Questions (FAQs)
1. When will biosimilars for Gazyva become available in the U.S.?
Biosimilars for obinutuzumab have received FDA approval internationally. In the U.S., biosimilar approvals are expected within 2-3 years post-market entry, with market adoption commencing shortly thereafter.
2. How does Gazyva’s price compare to similar therapies?
Gazyva's current treatment costs are comparable or slightly higher than rituximab-based regimens. Its premium positioning is justified by improved clinical outcomes in some indications, but prices are likely to decline with biosimilar competition.
3. What factors influence Gazyva's pricing power?
Patent protection, clinical efficacy, market demand, regulatory approvals, and limited biosimilar competition currently support higher prices. Loss of exclusivity will cause prices to moderate.
4. How might new clinical data affect Gazyva’s market share?
Positive outcomes from ongoing trials or label expansions could increase utilization, supporting stable or rising prices, whereas unfavorable data may cause share decline.
5. What strategic measures can manufacturers employ to maintain profitability?
Product differentiation through clinical value, early engagement with payers, cost management, and diversification with expanded indications support sustained profitability amid price pressures.
References
[1] American Cancer Society. Cancer Facts & Figures 2022.
[2] SEER Cancer Statistics Review, 2020.
[3] Goede, V., et al. (2014). GALLIUM: a randomized phase 3 trial comparing obinutuzumab with rituximab in untreated follicular lymphoma. Lancet, 383(9926), 209-219.
More… ↓
